Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load

Michael Frimpong, Bernadette Agbavor, Mabel Sarpong Duah, Aloysius Loglo, Francisca N Sarpong, Justice Boakye-Appiah, Kabiru M Abass, Mathias Dongyele, George Amofa, Wilson Tuah, Margaret Frempong, Yaw A Amoako, Mark Wansbrough-Jones, Richard O Phillips, Michael Frimpong, Bernadette Agbavor, Mabel Sarpong Duah, Aloysius Loglo, Francisca N Sarpong, Justice Boakye-Appiah, Kabiru M Abass, Mathias Dongyele, George Amofa, Wilson Tuah, Margaret Frempong, Yaw A Amoako, Mark Wansbrough-Jones, Richard O Phillips

Abstract

Background: We investigated the relationship between bacterial load in Buruli ulcer (BU) lesions and the development of paradoxical reaction following initiation of antibiotic treatment.

Methods: This was a longitudinal study involving BU patients from June 2013 to June 2017. Fine needle aspirates (FNA) and swab samples were obtained to establish the diagnosis of BU by PCR. Additional samples were obtained at baseline, during and after treatment (if the lesion had not healed) for microscopy, culture and combined 16S rRNA reverse transcriptase/ IS2404 qPCR assay. Patients were followed up at regular intervals until complete healing.

Results: Forty-seven of 354 patients (13%) with PCR confirmed BU had a PR, occurring between 2 and 42 (median 6) weeks after treatment initiation. The bacterial load, the proportion of patients with positive M. ulcerans culture (15/34 (44%) vs 29/119 (24%), p = 0.025) and the proportion with positive microscopy results (19/31 (61%) vs 28/90 (31%), p = 0.003) before initiation of treatment were significantly higher in the PR compared to the no PR group. Plaques (OR 5.12; 95% CI 2.26-11.61; p<0.001), oedematous (OR 4.23; 95% CI 1.43-12.5; p = 0.009) and category II lesions (OR 2.26; 95% CI 1.14-4.48; p = 0.02) were strongly associated with the occurrence of PR. The median time to complete healing (28 vs 13 weeks, p <0.001) was significantly longer in the PR group.

Conclusions: Buruli ulcer patients who develop PR are characterized by high bacterial load in lesion samples taken at baseline and a higher rate of positive M. ulcerans culture. Occurrence of a PR was associated with delayed healing.

Trial registration: ClinicalTrials.gov NCT02153034.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Flowchart of study participants, 2013–2017.
Fig 1. Flowchart of study participants, 2013–2017.
Fig 2. Typical paradoxical reactions in Buruli…
Fig 2. Typical paradoxical reactions in Buruli ulcer following antibiotic treatment.
A: New nodular lesion on the left thigh of a patient with an indurated lesion before antibiotic treatment, B: Paradoxically enlarged ulcer of lesion A during antibiotic therapy at week 4. C: Multiple new lesions (red arrows) around the original lesion on the left elbow (blue arrow) at week 5 of antibiotic treatment.
Fig 3. Increased bacterial load at baseline…
Fig 3. Increased bacterial load at baseline in patients who developed paradoxical reaction (PR+) in comparison to those who did not (PR-).
Higher viable M. ulcerans in lesions of patients who subsequently developed paradoxical reaction post treatment as measured by 16S rRNA at baseline compared those who did not. Each point represents the number of copies per milliliter (log10) of sample. The horizontal bars show the means and standard deviations of each group.
Fig 4. Images of 2 patients (A…
Fig 4. Images of 2 patients (A and B) who had positive 16S rRNA and culture results after 8 weeks of antibiotic treatment.
Patient A; Presented with a plaque on the right thigh with surrounding induration (week 0) which reduced significantly after antibiotic treatment (week 8). A new lesion appeared on the right knee at week 10 at the same time as the original lesion on the right thigh re-ulcerated (PR at week 10). Patient B; Presented with an ulcer on the left elbow (week 0), there was improvement after antibiotic treatment as evidenced by formation of clean granulation tissue with some epithelization (week 8). A new lesion was seen close to the initial lesion (PR at week 11).
Fig 5. Kaplan Meier analysis for time…
Fig 5. Kaplan Meier analysis for time to complete healing in Buruli ulcer patients who developed paradoxical reaction and those who did not following antibiotic treatment.
Broken lines indicate the median healing time (weeks) for each group.

References

    1. WHO. WHO Buruli ulcer (Mycobacterium ulcerans infection). Fact sheet N° 199. Geneva, Switzerland: WHO Health Organisation; updated 2017. Geneva, Switzerland2018 [updated 16 April 2018; cited 2018 23/11/2018]. .
    1. Ahorlu CK, Koka E, Yeboah-Manu D, Lamptey I, Ampadu E. Enhancing Buruli ulcer control in Ghana through social interventions: a case study from the Obom sub-district. BMC public health. 2013;13(1):59.
    1. Abass KM, Van Der Werf TS, Phillips RO, Sarfo FS, Abotsi J, Mireku SO, et al. Buruli ulcer control in a highly endemic district in Ghana: role of community-based surveillance volunteers. The American journal of tropical medicine and hygiene. 2015;92(1):115–7. 10.4269/ajtmh.14-0405
    1. Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. The Lancet. 2006;367(9525):1849–58.
    1. Ruf M-T, Chauty A, Adeye A, Ardant M-F, Koussemou H, Johnson RC, et al. Secondary Buruli Ulcer Skin Lesions Emerging Several Months after Completion of Chemotherapy: Paradoxical Reaction or Evidence for Immune Protection? PLOS Neglected Tropical Diseases. 2011;5(8):e1252 10.1371/journal.pntd.0001252
    1. Simonet V, Organization WH. Prevention of disability in buruli ulcer: basic rehabilitation: practical field guide. Geneva: World Health Organization, 2008.
    1. WHO. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. 2012.
    1. Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, Awuah PC, et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clinical infectious diseases. 2011;54(4):519–26. 10.1093/cid/cir856
    1. O’Brien DP, Robson M, Friedman ND, Walton A, McDonald A, Callan P, et al. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC infectious diseases. 2013;13(1):416.
    1. Barogui YT, Klis S-A, Johnson RC, Phillips RO, van der Veer E, van Diemen C, et al. Genetic susceptibility and predictors of paradoxical reactions in Buruli ulcer. PLoS neglected tropical diseases. 2016;10(4):e0004594 10.1371/journal.pntd.0004594
    1. Bretzel G, Siegmund V, Nitschke J, Herbinger K, Thompson W, Klutse E, et al. A stepwise approach to the laboratory diagnosis of Buruli ulcer disease. Tropical Medicine & International Health. 2007;12(1):89–96.
    1. Frimpong M, Sarpong-Duah M, Beissner M, Sarfo F, Loglo A, Tannor E, et al. Microscopy for Acid Fast Bacilli: A Useful but Neglected Tool in Routine Laboratory Diagnosis of Buruli Ulcer. J Trop Dis. 2015;3(158):2.
    1. Sarpong-Duah M, Frimpong M, Beissner M, Saar M, Laing K, Sarpong F, et al. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase/IS 2404 qPCR assay. PLoS neglected tropical diseases. 2017;11(7):e0005695 10.1371/journal.pntd.0005695
    1. O’Brien DP, Comte E, Serafini M, Ehounou G, Antierens A, Vuagnat H, et al. The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa. The Lancet Infectious Diseases. 2014;14(5):435–40. 10.1016/S1473-3099(13)70201-9
    1. Portaels F, Organization WH. Laboratory diagnosis of buruli ulcer: a manual for health care providers. 2014.
    1. Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng N-Y, Sarfo FS, et al. Detection of viable Mycobacterium ulcerans in clinical samples by a novel combined 16S rRNA reverse transcriptase/IS2404 real-time qPCR assay. 2012;6(8):e1756.
    1. Janssens N, Janicot M, Perera T, Bakker A. Housekeeping genes as internal standards in cancer research. Molecular Diagnosis. 2004;8(2):107–13.
    1. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. 2010;54(9):3678–85.
    1. Walker NF, Scriven J, Meintjes G, Wilkinson RJ. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV/AIDS (Auckland, NZ). 2015;7:49.
    1. Bibert S, Bratschi MW, Aboagye SY, Collinet E, Scherr N, Yeboah-Manu D, et al. Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms. Frontiers in microbiology. 2017;8:1903 10.3389/fmicb.2017.01903

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe